As Hims & Hers pivots to branded GLP-1s via a Novo Nordisk deal, all eyes are on the company’s May 11 earnings as investors look for sustained subscriber growth.
The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.
DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction,...
Barchart Research What to Expect from NVO Earnings NVO Generated May 5, 2026 Current Price $44.87 EPS Estimate $$0.87 Consensus Rating Hold Average Move 4.47% Novo Nordisk Reports Earnings While Trading...
Monday U.S. Featured Earnings Palantir Technologies Inc. (NASDAQ: PLTR) (Q1) EPS ...
Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.
Viking Therapeutics stock faces near-term pressure, but its GLP-1 pipeline and clinical timeline could deliver significant long-term upside
Amazon is stepping into the GLP-1 arena, with the consumer giant positioning itself as a competitor to Hims & Hers Health. Hims may have a problem on its hands.
/Eli%20Lilly%20and%20Co_%20by%20Sergio%20Photone%20via%20Shutterstock.jpg)
Eli Lilly shares sink as data shows Foundayo trailing Novo’s oral Wegovy. But there’s reason to consider buying LLY shares on the dip today.
/Amazon%20-%20Image%20by%20bluestork%20via%20Shutterstock.jpg)
Amazon is expanding into integrated weight-loss care with a scalable healthcare model. Can this expansion meaningfully drive AMZN stock upside?